Table 1.
Characteristic | NTRK efficacy-evaluable population (n = 121) | |
---|---|---|
Age, y | Median (range) | 57.0 (21–88) |
Sex, n (%) | Female/male | 62 (51.2)/59 (48.8) |
Race, n (%) | White/Asian/Black or African American/other or not reported | 73 (60.3)/29 (24.0)/3 (2.5)/16 (13.2) |
History of smoking (n = 118), n (%) | No/yes | 72 (61.0)/46 (39.0) |
ECOG PS, n (%) | 0/1/2 | 53 (43.8)/57 (47.1)/11 (9.1) |
Prior lines of systemic therapya, n (%) | 0/1/2/3/≥4 | 37 (30.6)/35 (28.9)/26 (21.5)/12 (9.9)/11 (9.1) |
Any previous therapyb, n (%) | Chemotherapy/targeted therapy/hormonal therapy/immunotherapy | 88 (72.7)/24 (19.8)/10 (8.3)/13 (10.7) |
CNS metastases at baselinec, n (%) | Present/measurable/absent | 20 (16.5)/6 (5.0)/95 (78.5) |
Prior radiotherapy of the braind (n = 26), n (%) | Yes/no | 17 (65.4)/9 (34.6) |
Time from end of prior radiotherapy of the brain to first dosee, n (%) | <2 mo/2 to <6 mo/≥6 mo | 7 (41.2)/5 (29.4)/5 (29.4) |
NTRK fusion, n (%) | NTRK1/NTRK2/NTRK3 | 48 (39.7)/6 (5.0)/67 (55.4) |
Tumor categoryf, n (%) | Sarcoma | 26 (21.5) |
Salivary (MASC) | 24 (19.8) | |
NSCLC | 22 (18.2) | |
Thyroid | 13 (10.7) | |
Colorectal | 10 (8.3) | |
Breast | 7 (5.8) | |
Neuroendocrine | 5 (4.1) | |
Pancreatic | 4 (3.3) | |
Cancer of unknown primary | 3 (2.5) | |
Gynecologic | 2 (1.7) | |
Head and neck (other) | 2 (1.7) | |
Cholangiocarcinoma | 1 (0.8) | |
Adenocarcinoma of upper GI tract | 1 (0.8) | |
Neuroblastoma | 1 (0.8) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastrointestinal; MASC, mammary analog secretory carcinoma.
aLines of therapy determined from the time of metastatic disease diagnosis.
bPrevious therapy in any setting.
cCNS metastases status as per investigator assessment.
dAmong patients with baseline CNS metastases per investigator assessment.
eAmong patients with baseline CNS metastases and prior radiotherapy of the brain.
fPatients may have had multiple sites of metastases at baseline.